Leaders from The US Oncology Network and McKesson discuss how technology can enhance precision medicine and improve patient access to cutting-edge cancer treatments.

While most of what the FDA laid out in a recent draft guidance on the assessment of overall survival in oncology clinical ...

Panelists discussed these questions during a recent Institute for Value-Based Medicine® event held in Nashville, Tennessee, ...

The state-of-the-workforce report identifies challenges in cancer care access across the US, particularly in rural areas.

Acquisition focused on lead clinical-stage program ICT01 in acute myeloid leukemia, where data from the ongoing Phase I/II EVICTION trial showed high treatment response ICT01 has the potential to be a ...

Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response rate, sustained improvement in desmoid tumor symptoms and con ...

The Cancer Gene Census (CGC) is a widely used module within the Catalogue Of Somatic Mutations In Cancer (COSMIC) that comprises an ongoing effort to catalogue and describe all genes with causal ...

Fox Chase Cancer Center announced the hiring of André Kydd, MD, PhD, as an Assistant Professor in the Department of ...

The 5th Binaytara Precision Oncology Summit, a two-day conference chaired by Dr. Mark Pegram, convenes in San Francisco on October 24-25, 2025. The summit is dedicated to redefining cancer treatment ...

Fox Chase Cancer Center announced the hiring of Saumya Maru, MD, PhD, as an Assistant Professor in the clinical ...

Leading clinicians, researchers & pharmaceutical innovators gathered to discuss the future of cancer treatment.

Robust survivorship care is important because cancer patients have a unique set of medical needs,” said Melissa Erickson, MD.